User:Blent/Seminar 07 fall: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
| (5 intermediate revisions by the same user not shown) | |||
| Line 17: | Line 17: | ||
*** [http://www.fda.gov/cder/genomics/default.htm Genomics at FDA] | *** [http://www.fda.gov/cder/genomics/default.htm Genomics at FDA] | ||
=== case study: CBZ-SJS === | === case study: CBZ-SJS === | ||
* [http://www.nature.com/nature/journal/v428/n6982/full/428486a.html Medical genetics: a marker for Stevens-Johnson syndrome, | * [http://www.nature.com/nature/journal/v428/n6982/full/428486a.html Medical genetics: a marker for Stevens-Johnson syndrome, 2004 April Nature] | ||
** HLA-B 1520 is an universal marker for Han Chinese in Taiwan | ** HLA-B 1520 is an universal marker for Han Chinese in Taiwan | ||
* [http://www.nature.com/tpj/journal/v6/n4/full/6500356a.html A marker for Stevens-Johnson syndrome ...: ethnicity matters, The Pharmacogenomics Journal | ** [http://brc.se.fju.edu.tw/protein/analysis/ms.htm MS蛋白質序列分析] | ||
** [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=12164776&dopt=AbstractPlus MALDI-TOF mass spectrometry-based SNP genotyping, 2002 Pharmacogenomics] | |||
** [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=11295828 High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems and promise, 2001 Hum Mutat.] | |||
* [http://www.nature.com/tpj/journal/v6/n4/full/6500356a.html A marker for Stevens-Johnson syndrome ...: ethnicity matters, 2006 The Pharmacogenomics Journal] | |||
** HLA-B 1502 may '''NOT''' be an universal marker for CBZ-SJS | ** HLA-B 1502 may '''NOT''' be an universal marker for CBZ-SJS | ||
* [http://www.nature.com/nrd/journal/v4/n1/full/nrd1605.html Genetic aspects of immune-mediated adverse drug effects, 2005 Nature] | |||
* [http://www.nature.com/jid/journal/v114/n1/full/5600617a.html Nitric Oxide Synthase in Toxic Epidermal Necrolysis and Stevens–Johnson Syndrome, 2000 Journal of Investigative Dermatology] | |||
* [http://sa.ylib.com/news/newsshow.asp?FDocNo=438&CL=28 嚴重藥物過敏，可以預防 (科學人 2004 May)] | * [http://sa.ylib.com/news/newsshow.asp?FDocNo=438&CL=28 嚴重藥物過敏，可以預防 (科學人 2004 May)] | ||
* [http://explore.pts.org.tw/p2.htm 公視 探索未知世界 第二集: 解毒生命密碼-基因與藥物過敏] | * [http://explore.pts.org.tw/p2.htm 公視 探索未知世界 第二集: 解毒生命密碼-基因與藥物過敏] | ||
| Line 28: | Line 33: | ||
* [http://www.epochtimes.com/b5/7/9/18/n1837459.htm 台灣獨步全球 預防抗癲癇藥害 - 明年起先測基因 首見研究成果當警語 (大紀元電子報 9/18, 2007)] | * [http://www.epochtimes.com/b5/7/9/18/n1837459.htm 台灣獨步全球 預防抗癲癇藥害 - 明年起先測基因 首見研究成果當警語 (大紀元電子報 9/18, 2007)] | ||
* [http://en.wikipedia.org/wiki/Carbamazepine Carbamazepine] is an long half-live drug | * [http://en.wikipedia.org/wiki/Carbamazepine Carbamazepine] is an long half-live drug | ||
=== case study: Warfarin (抗凝血劑) and dosage estimation === | === case study: Warfarin (抗凝血劑) and dosage estimation === | ||
* [http://www.aafp.org/afp/990201ap/635.html Warfarin Therapy: Evolving Strategies in Anticoagulation, Feb 1999, American Family Physician] | * [http://www.aafp.org/afp/990201ap/635.html Warfarin Therapy: Evolving Strategies in Anticoagulation, Feb 1999, American Family Physician] | ||
* [http://genome.wellcome.ac.uk/doc_WTD020935.html Genetic variation (VKORC1) alters response to warfarin, 2/6/05. By NIH/National Institute of General Medical Sciences] | * [http://genome.wellcome.ac.uk/doc_WTD020935.html Genetic variation (VKORC1) alters response to warfarin, 2/6/05. By NIH/National Institute of General Medical Sciences] | ||
* [http://www.clinchem.org/cgi/content/full/53/9/1721 Genetic Factors for Warfarin Dose Prediction, 2007 Clinical Chemistry] | |||
=== case study: Diabetes and Diagnosis === | === case study: Diabetes and Diagnosis === | ||
=== BioBank and Biomarkers discovery === | === BioBank and Biomarkers discovery === | ||
Latest revision as of 22:50, 1 October 2007
Title
- Toward Personalized Medicine in BMI-based Methodology: A case study of Carbamazepine and challenges in the future
Outlines (Sep 30, 2007)
What is personalized medicine
- personalized biomedical data collection and analysis
- easy-to-use personalized diagnosis kit
- personalized biomedical date-driven medicine usage
- which medicine should one take? (decision of medicine)
- how much medicine should one take? (dosage of medicine)
- references
- personalized medicine coalition
- Personalized Medicine in Cancer: Matching Patients and Drugs (Genome News Network, Oct 28th, 2004)
- Personalized medicine: A new approach to staying well (Boston Globe News, July 17th, 2005)
- Genomics and Personalized Medicine (FDA Consumer magazine, Nov-Dec 2005 issue)
case study: CBZ-SJS
- Medical genetics: a marker for Stevens-Johnson syndrome, 2004 April Nature
- HLA-B 1520 is an universal marker for Han Chinese in Taiwan
- MS蛋白質序列分析
- MALDI-TOF mass spectrometry-based SNP genotyping, 2002 Pharmacogenomics
- High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems and promise, 2001 Hum Mutat.
- A marker for Stevens-Johnson syndrome ...: ethnicity matters, 2006 The Pharmacogenomics Journal
- HLA-B 1502 may NOT be an universal marker for CBZ-SJS
- Genetic aspects of immune-mediated adverse drug effects, 2005 Nature
- Nitric Oxide Synthase in Toxic Epidermal Necrolysis and Stevens–Johnson Syndrome, 2000 Journal of Investigative Dermatology
- 嚴重藥物過敏，可以預防 (科學人 2004 May)
- 公視 探索未知世界 第二集: 解毒生命密碼-基因與藥物過敏
- 基因型鑑定 預防藥物過敏邁向個人化醫療 (中廣新聞網 3/8, 2007)
- 我國個人化醫療跨出一大步，讓藥害救濟由事後救濟邁向事前預防 (行政院衛生署藥物資訊網 9/17, 2007)
- 預防抗癲癇藥害 明年起先測基因 - 首見研究成果當警語 (自由時報生活新聞 9/18, 2007)
- 台灣獨步全球 預防抗癲癇藥害 - 明年起先測基因 首見研究成果當警語 (大紀元電子報 9/18, 2007)
- Carbamazepine is an long half-live drug
case study: Warfarin (抗凝血劑) and dosage estimation
- Warfarin Therapy: Evolving Strategies in Anticoagulation, Feb 1999, American Family Physician
- Genetic variation (VKORC1) alters response to warfarin, 2/6/05. By NIH/National Institute of General Medical Sciences
- Genetic Factors for Warfarin Dose Prediction, 2007 Clinical Chemistry
case study: Diabetes and Diagnosis
BioBank and Biomarkers discovery
case study: The First race-specific drug BiDil
- 活力藥師網番外篇-藥瓶裡的種族問題
- Race in a Bottle, Jonathan Kahn. (Sci Am 2007 Aug)
- 藥瓶裡的種族問題 科學人 2007 Sep
- author: Jonathan Kahn
- Are race-specific drugs unethical? With BiDil on the market, experts weigh the moral implications, Nov 2005
- BiDil: Isosorbide dinitrate and hydralazine
ELSI, Biobank and FDA guide lines
Movies
Outlines (Sep 20, 2007)
- BMI = BI + MI
- what BMI can do
- Neuroinformatics (NI)
- Cancer research (CR)
- what BMI can do
- Personalized Medicine (PM)
- Motivation and case study
- Stevens-Johnson syndrome and HLA-B 1502
- Methodology
- MI
- BI
- Products
- Problems remained
- Motivation and case study
Background
- intersection between Bioinformatics and Medical Informatics
- total search results
- Bioinformatics and Medical Informatics: Collaborations on the Road to Genomic Medicine? 2003 JAMIA
- The Interactions Between Clinical Informatics and Bioinformatics, 2000 JAMIA
- Opportunities at the Intersection of Bioinformatics and Health Informatics, 2000 JAMIA
- Training the Next Generation of Informaticians: The Impact of "BISTI" and Bioinformatics—A Report from the American College of Medical Informatics, 2004 JAMIA
- Military Research Needs in Biomedical Informatics, 2000 JAMIA
- Synergies in Medical Informatics and Bioinformatics
Materials
- Scientific American (English)
- Scientific American (Taiwan)
- BioIT
- Genetic Engineering & biotechnology News
- 華文生技網
- 科學人知識庫
